Helix BioPharma Corp. collaborator ProMab Biotechnologies to present at the CAR-TCR Summit 2018 in Boston

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc. (“ProMab”) will present at the CAR-TCR Summit 2018 being held from September 4th – 7th, 2018 in Boston, Massachusetts.

Dr. Vita Golubovskaya, Director, R&D, BD of Promab Biotechnologies will present on September 5th at 12:25pm. The title of the presentation is “Novel CAR-T Cells Against Solid and Hematological Cancers”.  Dr. Golubovskaya’s presentation will include certain preclinical data from the multiple myeloma project currently in collaboration with Helix.